

AMPICILLIN- ampicillin sodium injection, powder, for solution
APP Pharmaceuticals, Inc.

AMPICILLIN

FOR INJECTION, USP


Rx only

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

DESCRIPTION:

Ampicillin for Injection, USP, the monosodium salt of D(-)-6-(2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo [3.2.0] heptane-2-carboxylate is a sterile synthetic penicillin for intramuscular or intravenous use. It is an antibacterial agent with a broad spectrum of bactericidal activity against both penicillin-susceptible Gram-positive organisms and many common Gram-negative pathogens.

It has the following structural formula:



C₁₆H₁₈N₃NaO₄S

M.W. 371.39

Ampicillin for Injection contains approximately 2.9 milliequivalents of sodium per 1 gram of drug.

CLINICAL PHARMACOLOGY:

Ampicillin diffuses readily into most body tissues and fluids. However, penetration into the cerebrospinal fluid and brain occurs only when the meninges are inflamed. Ampicillin is excreted largely unchanged in the urine and its excretion can be delayed by concurrent administration of probenecid. The active form appears in the bile in higher concentrations than those found in serum. Ampicillin is the least serum-bound of all the penicillins, averaging about 20% compared to approximately 60 to 90% for other penicillins. Ampicillin is well tolerated by most patients and has been given in doses of 2 grams daily for many weeks without adverse reactions.

Microbiology

While *in vitro* studies have demonstrated the susceptibility of most strains of the following organisms, clinical efficacy for infections other than those included in the **INDICATIONS AND USAGE** section has not been demonstrated.

The following bacteria have been shown in *in vitro* studies to be susceptible to ampicillin:

Gram-positive Organisms

Hemolytic and nonhemolytic streptococci, *S. pneumoniae* (formerly *D. pneumoniae*), nonpenicillinase-producing staphylococci, *Clostridia* spp., *B. anthracis*, *Listeria monocytogenes*, and most strains of

enterococci.

Gram-negative Organisms

H. influenzae, *N. gonorrhoeae*, *N. meningitidis*, *Proteus mirabilis*, and many strains of *Salmonella*, *Shigella*, and *E. coli*.

Ampicillin does not resist destruction by penicillinase.

Susceptibility Tests

Ampicillin Susceptibility Test Discs, 10 mcg, should be used to estimate the *in vitro* susceptibility of bacteria to ampicillin.

INDICATIONS AND USAGE:

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection and other antibacterial drugs, Ampicillin for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Ampicillin for Injection is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below:

Respiratory Tract Infections caused by *S. pneumoniae*, *Staphylococcus aureus* (penicillinase and nonpenicillinase-producing), *H. influenzae*, and Group A beta-hemolytic streptococci.

Bacterial Meningitis caused by *E. coli*, Group B streptococci, and other Gram-negative bacteria (*Listeria monocytogenes*, *N. meningitidis*). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria.

Septicemia and Endocarditis caused by susceptible Gram-positive organisms including *Streptococcus* sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by *E. coli*, *Proteus mirabilis* and *Salmonella* sp. respond to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptococcal endocarditis.

Urinary Tract Infections caused by sensitive strains of *E. coli* and *Proteus mirabilis*.

Gastrointestinal Infections caused by *Salmonella typhosa* (typhoid fever), other *Salmonella* sp., and *Shigella* sp. (dysentery) usually respond to oral or intravenous therapy.

Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing.

It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate.

Indicated surgical procedures should be performed.

CONTRAINDICATIONS:

A history of a previous hypersensitivity reaction to any of the penicillins is a contraindication.

WARNINGS:

Serious and occasionally fatal hypersensitivity (anaphylactoid) reactions have been reported in patients

on penicillin therapy. Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more apt to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens.

There have been well-documented reports of individuals with a history of penicillin hypersensitivity reactions who have experienced severe hypersensitivity reactions when treated with a cephalosporin. Before initiating therapy with a penicillin, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, and other allergens. If an allergic reaction occurs, the drug should be discontinued and appropriate therapy instituted.

SERIOUS ANAPHYLACTOID REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE.

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED.

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Ampicillin for Injection, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated.

PRECAUTIONS:

General

Prescribing Ampicillin for Injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

The possibility of superinfections with mycotic organisms or bacterial pathogens should be kept in mind during therapy. In such cases, discontinue the drug and substitute appropriate treatment.

A high percentage (43 to 100 percent) of patients with infectious mononucleosis who receive ampicillin develop a skin rash. Typically, the rash appears 7 to 10 days after the start of oral ampicillin therapy and remains for a few days to a week after the drug is discontinued. In most cases, the rash is maculopapular, pruritic, and generalized. Therefore, the administration of ampicillin is not recommended in patients with mononucleosis. It is not known whether these patients are truly allergic to ampicillin.

Information for Patients

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

Patients should be counseled that antibacterial drugs including Ampicillin for Injection should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Ampicillin for Injection is prescribed to treat a bacterial infection, patients should be told that although

it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Ampicillin for Injection or other antibacterial drugs in the future.

Laboratory Tests

As with any potent drug, periodic assessment of organ system function, including renal, hepatic, and hematopoietic, should be made during prolonged therapy.

Transient elevation of serum transaminase has been observed following administration of ampicillin. The significance of this finding is not known.

Drug Interactions

The concurrent administration of allopurinol and ampicillin increases substantially the incidence of skin rashes in patients receiving both drugs as compared to patients receiving ampicillin alone. It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.

Drug/Laboratory Test Interactions

With high urine concentrations of ampicillin, false-positive glucose reactions may occur if Clinitest, Benedict's Solution, or Fehling's Solution are used. Therefore, it is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix or Tes-Tape [Glucose Enzymatic Test Strip USP]) be used.

Carcinogenesis, Mutagenesis, and Impairment of Fertility

No long-term animal studies have been conducted with this drug.

Pregnancy Category B

Reproduction studies have been performed in laboratory animals at doses several times the human dose and have revealed no evidence of adverse effects to ampicillin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Labor and Delivery

Oral ampicillin-class antibiotics are poorly absorbed during labor. Studies in guinea pigs showed that intravenous administration of ampicillin slightly decreased the uterine tone and frequency of contractions, but moderately increased the height and duration of contractions. However, it is not known whether use of these drugs in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary.

Nursing Mothers

Ampicillin is excreted in trace amounts in human milk. Therefore, caution should be exercised when ampicillin-class antibiotics are administered to a nursing woman.

Pediatric Use

Guidelines for the administration of these drugs to children are presented in **DOSAGE AND ADMINISTRATION**.

ADVERSE REACTIONS:

As with other penicillins, it may be expected that untoward reactions will be essentially limited to sensitivity phenomena. They are more likely to occur in individuals who have previously demonstrated hypersensitivity to penicillins and in those with a history of allergy, asthma, hay fever, or urticaria.

The following adverse reactions have been reported as associated with the use of ampicillin.

Gastrointestinal

Glossitis, stomatitis, black "hairy" tongue, nausea, vomiting, enterocolitis, pseudomembranous colitis, and diarrhea. (These reactions are usually associated with oral dosage forms.)

Hypersensitivity Reactions

Skin rashes and urticaria have been reported frequently. A few cases of exfoliative dermatitis and erythema multiforme have been reported. Anaphylaxis is the most serious reaction experienced and has usually been associated with the parenteral dosage form. **Note:** Urticaria, other skin rashes, and serum sickness-like reactions may be controlled with antihistamines and, if necessary, systemic corticosteroids. Whenever such reactions occur, ampicillin should be discontinued, unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to ampicillin therapy. Serious anaphylactic reactions require the immediate use of epinephrine, oxygen, and intravenous steroids.

Liver

A moderate rise in serum glutamic oxaloacetic transaminase (SGOT) has been noted, particularly in infants, but the significance of this finding is unknown. Mild transitory SGOT elevations have been observed in individuals receiving larger (two to four times) than usual and oft-repeated intramuscular injections. Evidence indicates that glutamic oxaloacetic transaminase (GOT) is released at the site of intramuscular injection of ampicillin and that the presence of increased amounts of this enzyme in the blood does not necessarily indicate liver involvement.

Hemic and Lymphatic Systems

Anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia, and agranulocytosis have been reported during therapy with the penicillins. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena.

OVERDOSAGE:

In cases of overdose, discontinue medication, treat symptomatically and institute supportive measures as required. In patients with renal function impairment, ampicillin-class antibiotics can be removed by hemodialysis but not peritoneal dialysis.

DOSAGE AND ADMINISTRATION:

Infections of the respiratory tract and soft tissues.

Patients weighing 40 kg (88 lbs) or more: 250 to 500 mg every 6 hours.

Patients weighing less than 40 kg (88 lbs): 25 to 50 mg/kg/day in equally divided doses at 6 to 8 hour intervals.

Infections of the gastrointestinal and genitourinary tracts (including those caused by *Neisseria gonorrhoeae* in females).

Patients weighing 40 kg (88 lbs) or more: 500 mg every 6 hours.

Patients weighing less than 40 kg (88 lbs): 50 mg/kg/day in equally divided doses at 6 to 8 hour

intervals.

In the treatment of chronic urinary tract and intestinal infections, frequent bacteriological and clinical appraisal is necessary. Smaller doses than those recommended above should not be used. Higher doses should be used for stubborn or severe infections. In stubborn infections, therapy may be required for several weeks. It may be necessary to continue clinical and/or bacteriological follow-up for several months after cessation of therapy.

Urethritis in males due to *N. gonorrhoeae*.

Adults: Two doses of 500 mg each at an interval of 8 to 12 hours. Treatment may be repeated if necessary or extended if required.

In the treatment of complications of gonorrheal urethritis, such as prostatitis and epididymitis, prolonged and intensive therapy is recommended. Cases of gonorrhea with a suspected primary lesion of syphilis should have darkfield examinations before receiving treatment. In all other cases where concomitant syphilis is suspected, monthly serological tests should be made for a minimum of four months.

The doses for the preceding infections may be given by either the intramuscular or intravenous route. A change to oral ampicillin may be made when appropriate.

Bacterial Meningitis

Adults and children: 150 to 200 mg/kg/day in equally divided doses every 3 to 4 hours. (Treatment may be initiated with intravenous infusion therapy and continued with intramuscular injections.) The doses for other infections may be given by either the intravenous or intramuscular route.

Septicemia

Adults and children: 150 to 200 mg/kg/day. Start with intravenous administration for at least 3 days and continue with the intramuscular route every 3 to 4 hours.

Treatment of all infections should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. A minimum of 10-days treatment is recommended for any infection caused by Group A beta-hemolytic streptococci to help prevent the occurrence of acute rheumatic fever or acute glomerulonephritis.

DIRECTIONS FOR USE:

Use only fresh prepared solutions. Intramuscular and intravenous injections should be administered within one hour after preparation, since the potency may decrease significantly after this period.

For Intramuscular Use

Dissolve the contents of a vial with the amount of Sterile Water for Injection or Bacteriostatic Water for Injection listed in the table below:

NDC No.	Label Claim	Amount of Diluent to be Added (mL)	Approximate Available Volume (mL)	Approximate Concentration (in mg/mL)
63323-387-10	250 mg	0.9	1	250
63323-388-10	500 mg	1.7	2	250
63323-389-10	1 g	3.4	4	250
63323-399-23	2 g	6.8	8	250

While ampicillin for injection 1 g and 2 g vials are primarily for intravenous use, the contents may be administered intramuscularly when the 250 mg or 500 mg vials are unavailable. In such instances, dissolve in 3.4 or 6.8 mL Sterile Water for Injection or Bacteriostatic Water for Injection respectively.

The resulting solution will provide a concentration of 250 mg per mL.

For Direct Intravenous Use

Add 5 mL Sterile Water for Injection or Bacteriostatic Water for Injection to the 250 and 500 mg vials and administer slowly over a 3 to 5 minute period. Ampicillin for Injection, 1 g or 2 g, may also be given by direct intravenous administration. Dissolve in 7.4 or 14.8 mL Sterile Water for Injection or Bacteriostatic Water for Injection, respectively, and administer slowly over at least 10 to 15 minutes. CAUTION: More rapid administration may result in convulsive seizures.

For Administration by Intravenous Drip

Reconstitute as directed above (***For Direct Intravenous Use***) prior to diluting with intravenous solution. Stability studies on ampicillin at several concentrations in various intravenous solutions indicate the drug will lose less than 10% activity at the temperatures noted for the time periods stated.

Room Temperature (25°C)		
Diluent	Concentrations	Stability Periods
Sterile Water for Injection	up to 30 mg/mL	8 hours
Sodium Chloride Injection USP, 0.9%	up to 30 mg/mL	8 hours
M/6 Sodium Lactate Injection	up to 30 mg/mL	8 hours
5% Dextrose in Water	10 to 20 mg/mL	2 hours
5% Dextrose in Water	up to 2 mg/mL	4 hours
5% Dextrose in 0.45% NaCl Inj.	up to 2 mg/mL	4 hours
10% Invert Sugar in Water	up to 2 mg/mL	4 hours
Lactated Ringer's Injection	up to 30 mg/mL	8 hours
Refrigerated (4°C)		
Diluent	Concentrations	Stability Periods
Sterile Water for Injection	30 mg/mL	48 hours
Sterile Water for Injection	up to 20 mg/mL	72 hours
Sodium Chloride Injection USP, 0.9%	30 mg/mL	48 hours
Sodium Chloride Injection USP, 0.9%	up to 20 mg/mL	72 hours
Lactated Ringer's Injection	up to 30 mg/mL	24 hours
M/6 Sodium Lactate Injection	up to 30 mg/mL	8 hours
5% Dextrose in Water	up to 20 mg/mL	4 hours
5% Dextrose and 0.45% NaCl Inj.	up to 10 mg/mL	4 hours
10% Inver Sugar	up to 20 mg/mL	3 hours

Only those solutions listed above should be used for the intravenous infusion of Ampicillin for Injection. The concentrations should fall within the range specified. The drug concentration and the rate and volume of the infusion should be adjusted so that the total dose of ampicillin is administered before the drug loses its stability in the solution in use.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

HOW SUPPLIED:

Ampicillin for Injection, USP for IM or IV Injection. Ampicillin sodium equivalent to 250, 500 mg, 1 or 2 grams of ampicillin per vial.

Product	NDC
No.	No.

308710	63323-387-10	250 mg vial
308810	63323-388-10	500 mg vial
308910	63323-389-10	1 g vial
309923	63323-399-23	2 g vial

Packaged in tens.

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Vial stoppers do not contain natural rubber latex.

Manufactured for:


APP Pharmaceuticals, LLC
Schaumburg, IL 60173

Made in Italy

45931F

Revised: November 2007

805103/05

PRINCIPAL DISPLAY PANEL - 250 mg per Vial

NDC 63323-387-10

308710


AMPICILLIN
FOR INJECTION, USP

ampicillin sodium equivalent to
250 mg
ampicillin

For IV or IM Use

Rx only

10 Vials




PRINCIPAL DISPLAY PANEL - 500 mg per Vial

NDC 63323-388-10
308810

AMPICILLIN
FOR INJECTION, USP

ampicillin sodium equivalent to
500 mg
ampicillin

For IV or IM Use
Rx only
10 Vials




PRINCIPAL DISPLAY PANEL - 1 g per Vial

NDC 63323-389-10
308910

AMPICILLIN
FOR INJECTION, USP

ampicillin sodium equivalent to
1 g
ampicillin

For IV or IM Use
Rx only
10 Vials




PRINCIPAL DISPLAY PANEL - 2 g per Vial

NDC 63323-399-23
309923

AMPICILLIN
FOR INJECTION, USP

ampicillin sodium equivalent to
2 g
ampicillin

For IV Use
Rx only
10 Vials



AMPICILLIN

ampicillin sodium injection, powder, for solution

Product Information

Product Type

HUMAN PRESCRIPTION DRUG

Item Code (Source)

NDC:63323-387

Route of Administration

INTRAMUSCULAR,
INTRAVENOUS

DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
AMPICILLIN SODIUM (UNII: JFN36L5S8K) (AMPICILLIN - UNII:7C782967RD)	AMPICILLIN	250 mg

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:63323-387-10	10 in 1 CARTON		
1		1 in 1 VIAL		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA062719	05/12/1987	

AMPICILLIN

ampicillin sodium injection, powder, for solution

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:63323-388
Route of Administration	INTRAMUSCULAR, INTRAVENOUS	DEA Schedule	

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
AMPICILLIN SODIUM (UNII: JFN36L5S8K) (AMPICILLIN - UNII:7C782967RD)	AMPICILLIN	500 mg

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:63323-388-10	10 in 1 CARTON		
1		1 in 1 VIAL		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA062719	05/12/1987	

AMPICILLIN

ampicillin sodium injection, powder, for solution

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:63323-389
Route of Administration	INTRAMUSCULAR, INTRAVENOUS	DEA Schedule	

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
AMPICILLIN SODIUM (UNII: JFN36L5S8K) (AMPICILLIN - UNII:7C782967RD)	AMPICILLIN	1 g

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:63323-389-10	10 in 1 CARTON		
1		1 in 1 VIAL		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA062719	05/12/1987	

AMPICILLIN

ampicillin sodium injection, powder, for solution

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:63323-399
Route of Administration	INTRAMUSCULAR, INTRAVENOUS	DEA Schedule	

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
AMPICILLIN SODIUM (UNII: JFN36L5S8K) (AMPICILLIN - UNII:7C782967RD)	AMPICILLIN	2 g

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:63323-399-23	10 in 1 CARTON		
1		1 in 1 VIAL		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA062797	07/12/1993	

Labeler - APP Pharmaceuticals, Inc. (608775388)

Registrant - Istituto Biochimico Italiano Giovanni Lorenzini SpA (432432581)

Establishment

Name	Address	ID/FEI	Business Operations
Istituto Biochimico Italiano Giovanni Lorenzini SpA		432432581	manufacture(63323-387, 63323-388, 63323-389, 63323-399)

Revised: 11/2007

APP Pharmaceuticals, Inc.